A clinical trial study showed that treatment with lobeglitazone, a dual PPARα/δ agonist, at a dose of 0.5 mg daily for 24 weeks, significantly improved glycemic, hepatic steatosis, and serum enzymes for liver damage in T2DM patients with NAFLD [21]. Here, PPARA is linked to type 2 diabetes mellitus.